Drugs / Samalizumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02987504 | Nov 2016 → Sep 2017 | cancer | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00648739 | Jun 2008 → Dec 2010 | B-cell chronic lymphocytic leukemia, plasma cell myeloma | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03013998 | Nov 2016 → Dec 2032 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Samalizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03013998 ↗ |
| Known as | ALXN-6000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743067 ↗ |
| Action | Inhibit | “as a CD200 immune checkpoint inhibitor” PMID 31443741 ↗ Aug 2019 |
| Modality | Monoclonal antibody | “Samalizumab is a humanized anti-CD200 monoclonal antibody.” NCT00648739 ↗ |
| Route | Intravenous | “received a single IV dose of samalizumab.” NCT00648739 ↗ |
| Target | CD200 | “Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens...” PMID 31443741 ↗ Aug 2019 |